12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
| Status: | Terminated |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 10/5/2018 |
| Start Date: | June 20, 2017 |
| End Date: | July 27, 2018 |
A 12-Week Open-Label Extension Study to Evaluate TNX-102 SL Taken Daily at Bedtime in Patients With PTSD
This is an open-label, extension trial designed to evaluate safety over 12 additional weeks
of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD. Patients recruited
into this trial are those who have successfully completed the double-blind lead-in study.
of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD. Patients recruited
into this trial are those who have successfully completed the double-blind lead-in study.
The study will consist of 5 study visits, including Screening/Baseline Visit 1 (Day 0, which
is anticipated to be the same visit as the last visit on double-blind treatment), a phone
visit after 2 weeks of treatment, and in-clinic visits after 4, 8, and 12 weeks of treatment.
The primary objective of the study is to evaluate the safety of TNX-102 SL tablets taken
daily at bedtime over an additional 12 weeks in patients with PTSD who have completed a
double-blinded lead-in study.
The secondary objective of the study is to evaluate the efficacy of TNX-102 SL tablets taken
daily at bedtime over an additional 12 weeks in patients with PTSD who have completed a
double-blinded lead-in study.
is anticipated to be the same visit as the last visit on double-blind treatment), a phone
visit after 2 weeks of treatment, and in-clinic visits after 4, 8, and 12 weeks of treatment.
The primary objective of the study is to evaluate the safety of TNX-102 SL tablets taken
daily at bedtime over an additional 12 weeks in patients with PTSD who have completed a
double-blinded lead-in study.
The secondary objective of the study is to evaluate the efficacy of TNX-102 SL tablets taken
daily at bedtime over an additional 12 weeks in patients with PTSD who have completed a
double-blinded lead-in study.
Inclusion Criteria:
- The patient has completed the final treatment study visit of the lead-in study and
remained compliant with the lead-in protocol and study treatment.
- The patient has provided written informed consent to participate in this extension
protocol.
- Female patients of childbearing potential continue to agree to practice one of the
medically acceptable methods of birth control detailed in the lead-in study.
Exclusion Criteria:
We found this trial at
31
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials